Looking for our Business Solutions? Click here:CloudQuote APIsContact Us

Boston Scientific (BSX)

44.34
+0.14 (0.32%)
NYSE · Last Trade: Nov 13th, 5:13 PM EST
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close44.20
Open44.69
Bid44.20
Ask44.50
Day's Range44.08 - 44.69
52 Week Range39.57 - 105.65
Volume9,696,924
Market Cap63.13B
PE Ratio (TTM)18.79
EPS (TTM)2.4
Dividend & YieldN/A (N/A)
1 Month Average Volume19,560,888

Chart

About Boston Scientific (BSX)

Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More

News & Press Releases

Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 2027marketbeat.com
Boston Scientific (NYSE:BSX) executives said they expect durable growth across the company’s interventional portfolio, while acknowledging that its pulsed field ablation and WATCHMAN businesses face competitive challenges through 2027. Lance Bates, executive vice president and president of interven
Via MarketBeat · November 11, 2026
Insider Buying Signals: 3 Healthcare Stocks to Watchinvestorplace.com
Insider buying and share buybacks have put Prothena, Rapport Therapeutics and Azenta on the radar. See the catalysts and risks behind each stock.
Via InvestorPlace · November 11, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
NEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
By Pomerantz LLP · Via GlobeNewswire · November 10, 2026
S&P 500 Top Movers: Gainers and Losers on Nov. 6, 2026chartmill.com
Via Chartmill · November 6, 2026
Boston Scientific (NYSE:BSX) Q3 2026 Results In Line, Stock Slips Premarketchartmill.com
Via Chartmill · October 28, 2026
BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation’s Directors and Officers for Breach of Fiduciary Duties – BSX
Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) failed to manage Boston Scientific in an acceptable manner, breaching their fiduciary duties to Boston Scientific, and whether Boston Scientific and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:
By Scott+Scott Attorneys at Law LLP · Via Business Wire · November 5, 2026
Medical devices & supplies - diversified stocks Q3 teardown: Boston Scientific (NYSE:BSX) vs the rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q3. Today, we are looking a...
Via StockStory · November 3, 2026
Boston Scientific Q3 Earnings Call Highlightsmarketbeat.com
Boston Scientific (NYSE:BSX) reported third-quarter 2026 results that fell below its prior guidance after a cybersecurity incident disrupted manufacturing and product shipments for eight business days, while competitive and pricing pressures weighed on key cardiovascular franchises. Organic revenue
Via MarketBeat · October 29, 2026
Boston Scientific: 3 Key Takeaways for Long-Term Investorsfool.com
Cost cuts and pipeline launches aim to restore growth momentum after 2027 headwinds flatten earnings.
Via The Motley Fool · October 29, 2026
Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impactfool.com
Today, Oct. 28, 2026, the medical device maker slashed profit expectations after an August cyberattack continued disrupting operations.
Via The Motley Fool · October 28, 2026
S&P 500 Top Movers: Gainers and Losers in Today's US Sessionchartmill.com
Via Chartmill · October 28, 2026
S&P 500 Most Active Stocks for October 28, 2026chartmill.com
Via Chartmill · October 28, 2026
Boston Scientific (BSX) Q3 2026 Earnings Call Transcriptfool.com
Cybersecurity disruption and competitive pressures weighed on third-quarter results.
Via The Motley Fool · October 28, 2026
Why Boston Scientific (BSX) shares are plunging today
What happened? Shares of medical device company Boston Scientific (NYSE:BSX) fell 8% in the morning session after the company reported third-quarter 2026 fin...
Via StockStory · October 28, 2026
S&P 500 Gap Movers: Oct. 28 Sessionchartmill.com
Via Chartmill · October 28, 2026
S&P 500 Premarket Movers for Oct. 28, 2026chartmill.com
Via Chartmill · October 28, 2026
Boston Scientific (NYSE:BSX) posts better-than-expected sales in Q3 2026 but quarterly revenue guidance misses expectations
Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q3 2026, with revenue rising 1.4% year on year to $5.14 billion...
Via StockStory · October 28, 2026
Earnings to watch: Boston Scientific (BSX) reports Q3 results tomorrow
Medical device company Boston Scientific (NYSE:BSX) will be reporting results this Wednesday before market open. Here’s what to look for. Boston Scientific b...
Via StockStory · October 26, 2026
BOSTON SCIENTIFIC CORPORATION INVESTOR ALERT:  Scott+Scott Attorneys at Law LLP Investigates Boston Scientific Corporation’s Directors and Officers for Breach of Fiduciary Duties – BSX
Scott+Scott Attorneys at Law LLP has launched an urgent investigation into whether certain officers and directors of Boston Scientific Corporation (NYSE: BSX) failed to manage Boston Scientific in an acceptable manner, breaching their fiduciary duties to Boston Scientific, and whether Boston Scientific and its shareholders have suffered damages as a result. Attorney Joseph A. Pettigrew is heading the investigation—what shareholders need to know:
By Scott+Scott Attorneys at Law LLP · Via Business Wire · October 22, 2026
1 Stock Under $50 with Exciting Potential and 2 We Question
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However...
Via StockStory · October 21, 2026
1 Safe-and-Steady Stock to Research Further and 2 Facing Challenges
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. Fi...
Via StockStory · October 8, 2026
2 Cash-Producing Stocks Worth Investigating and 1 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff...
Via StockStory · October 5, 2026
2 Oversold Stocks Primed to Rebound and 1 We Find Risky
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether...
Via StockStory · October 2, 2026
2 Profitable Stocks to Research Further and 1 We Avoid
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via StockStory · October 1, 2026
2 Value Stocks with Exciting Potential and 1 We Avoid
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
Via StockStory · September 22, 2026